Chemotherapy plus targeted therapy for colorectal cancer liver metastases
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (FULIRI) plus targeted therapy to shrink liver tumors in people with colorectal cancer, with the goal of making surgery possible later. It is designed for people who haven't had systemic treatment for their liver metastasis yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to the liver (liver metastasis).
- You have not received any systemic treatment (like chemotherapy or targeted therapy) for the liver metastasis.
- Your doctors have determined that the liver tumors cannot be removed surgically right now, or they are hard to remove.
- You have at least one tumor that can be measured on a CT scan.
- You are generally able to take care of yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (tislelizumab, fruquintinib, and chidamide) for colorectal cancer that has spread to the liver and has not responded to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial tests giving patients a type of chemotherapy called FOLFIRI after they have had surgery to remove colorectal cancer that spread to the liver. The goal is to see if this additional treatment helps prevent the cancer from coming back, for patients who could not have a different chemotherapy before surgery.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.